We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will ...

Denmark’s Novo Nordisk has presented data at the European Congress of Obesity (ECO) showing that Wegovy (semaglutide ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Landmark' data has revealed a popular weight loss medicine slashes the risk of heart attack, stroke or heart disease death ...

The drugs help severely obese children to lose weight on top of the diet and lifestyle plan they are already following.

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Novo Nordisk will present data at the European Congress of Obesity (ECO) from a secondary, post hoc analysis of the SELECT ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Ozempic is a prescription drug used to deal with conditions related to high blood sugar levels and for diabetes management.